Results
eNauka >
Rezultati >
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
| Naziv: | Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial | Autori  : | Grosicki, Sebastian; ...; Bila, Jelena S.   ; ...; (broj koautora 58) |
Godina: | 2020 | Publikacija: | Lancet | ISSN: | 0140-6736 Lancet Pretraži identifikator |
Izdavač: | London : Elsevier | Tip rezultata: | Naučni članak | Kolacija: | vol. 396 br. 10262 str. 1563-1573 | DOI: | 10.1016/S0140-6736(20)32292-3 | WoS-ID: | 000588778800028 | Scopus-ID: | 2-s2.0-85096152969 | PMID: | 33189178 | URI: | https://enauka.gov.rs/handle/123456789/797056 | URL: | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32292-3/abstract | Projekat: | Karyopharm Therapeutics | Izvor metapodataka: | (Preuzeto iz Nasi u WoS) | M-kategorija: | 21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+ |
Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.